PMID- 38081519
OWN - NLM
STAT- MEDLINE
DCOM- 20240115
LR  - 20240115
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
VI  - 253
DP  - 2024 Jan
TI  - Clinical advances in TNC delivery vectors and their conjugate agents.
PG  - 108577
LID - S0163-7258(23)00241-3 [pii]
LID - 10.1016/j.pharmthera.2023.108577 [doi]
AB  - Tenascin C (TNC), a glycoprotein that is abundant in the tumor extracellular 
      matrix (ECM), is strongly overexpressed in tumor tissues but virtually 
      undetectable in most normal tissues. Many TNC antibodies, peptides, aptamers, and 
      nanobodies have been investigated as delivery vectors, including 20A1, alpha-A2, 
      alpha-A3, alpha-IIIB, alpha-D, BC-2, BC-4 BC-8, 81C6, ch81C6, F16, FHK, Ft, Ft-NP, G11, 
      G11-iRGD, GBI-10, 19H12, J1/TN1, J1/TN2, J1/TN3, J1/TN4, J1/TN5, NJT3, NJT4, 
      NJT6, P12, PL1, PL3, R6N, SMART, ST2146, ST2485, TN11, TN12, TNFnA1A2-Fc, 
      TNfnA1D-Fc, TNfnBD-Fc, TNFnCD-Fc, TNfnD6-Fc, TNfn78-Fc, TTA1, TTA1.1, and TTA1.2. 
      In particular, BC-2, BC-4, 81C6, ch81C6, F16, FHK, G11, PL1, PL3, R6N, ST2146, 
      TN11, and TN12 have been tested in human tissues. G11-iRGD and simultaneous 
      multiple aptamers and arginine-glycine-aspartic acid (RGD) targeting (SMART) may 
      be assessed in clinical trials because G11, iRGD and AS1411 (SMART components) 
      are already in clinical trials. Many TNC-conjugate agents, including 
      antibody-drug conjugates (ADCs), antibody fragment-drug conjugates (FDCs), 
      immune-stimulating antibody conjugates (ISACs), and radionuclide-drug conjugates 
      (RDCs), have been investigated in preclinical and clinical trials. RDCs 
      investigated in clinical trials include (111)In-DTPA-BC-2, (131)I-BC-2, 
      (131)I-BC-4, (90)Y-BC4, (131)I81C6, (131)I-ch81C6, (211)At-ch81C6, F16(124)I, 
      (131)I-tenatumomab, ST2146biot, FDC (131)I-F16S1PF(ab')2, and ISAC F16IL2. ADCs 
      (including FHK-SSL-Nav, FHK-NB-DOX, Ft-NP-PTX, and F16*-MMAE) and ISACs (IL12-R6N 
      and (125)I-G11-IL2) may enter clinical trials because they contain components of 
      marketed treatments or agents that were investigated in previous clinical 
      studies. This comprehensive review presents historical perspectives on clinical 
      advances in TNC-conjugate agents to provide timely information to facilitate 
      tumor-targeting drug development using TNC.
CI  - Copyright (c) 2023. Published by Elsevier Inc.
FAU - Chen, Wujun
AU  - Chen W
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong 266000, China.
FAU - Wu, Yudong
AU  - Wu Y
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong 266000, China.
FAU - Wang, Jie
AU  - Wang J
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong 266000, China.
FAU - Yu, Wanpeng
AU  - Yu W
AD  - Qingdao Medical College, Qingdao University, Qingdao, Shandong 266071, China.
FAU - Shen, Xin
AU  - Shen X
AD  - State Key Laboratory Base of Eco-chemical Engineering, College of Chemical 
      Engineering, Qingdao University of Science and Technology, Qingdao, Shandong 
      266042, China.
FAU - Zhao, Kai
AU  - Zhao K
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong 266000, China; Department 
      of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, Shandong 
      266000, China.
FAU - Liang, Bing
AU  - Liang B
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong 266000, China.
FAU - Hu, Xiaokun
AU  - Hu X
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong 266000, China; 
      Interventional Medicine Center, The Affiliated Hospital of Qingdao University, 
      Qingdao, Shandong 266000, China.
FAU - Wang, Shuai
AU  - Wang S
AD  - Department of Radiotherapy, Affiliated Hospital of Weifang Medical University, 
      Key Laboratory of Precision Radiation Therapy for Tumors in Weifang City, School 
      of Medical Imaging, Weifang Medical University, Weifang, Shandong 261031, China.
FAU - Jiang, Hongfei
AU  - Jiang H
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong 266000, China.
FAU - Liu, Xinlin
AU  - Liu X
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong 266000, China.
FAU - Zhang, Miao
AU  - Zhang M
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong 266000, China.
FAU - Xing, Xiaohui
AU  - Xing X
AD  - Department of Neurosurgery, Liaocheng People's Hospital, Liaocheng, Shandong 
      252000, China. Electronic address: xingxiaohuixxh@163.com.
FAU - Wang, Chao
AU  - Wang C
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong 266000, China. Electronic 
      address: wangchao20086925@126.com.
FAU - Xing, Dongming
AU  - Xing D
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao 
      University, Qingdao Cancer Institute, Qingdao, Shandong 266000, China; School of 
      Life Sciences, Tsinghua University, Beijing 100084, China. Electronic address: 
      xdm_tsinghua@163.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231209
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Tenascin)
RN  - 0 (Peptides)
RN  - 0 (Immunoconjugates)
SB  - IM
MH  - Humans
MH  - *Tenascin
MH  - Extracellular Matrix
MH  - Peptides
MH  - *Immunoconjugates/therapeutic use
MH  - Cell Line, Tumor
OTO - NOTNLM
OT  - Delivery vector
OT  - ISACs
OT  - RDCs
OT  - TNC
OT  - cancer agent development
COIS- Declaration of Competing Interest The authors declare no conflicts of interest 
      associated with this paper.
EDAT- 2023/12/12 00:42
MHDA- 2024/01/15 12:43
CRDT- 2023/12/11 19:26
PHST- 2023/10/09 00:00 [received]
PHST- 2023/12/02 00:00 [revised]
PHST- 2023/12/04 00:00 [accepted]
PHST- 2024/01/15 12:43 [medline]
PHST- 2023/12/12 00:42 [pubmed]
PHST- 2023/12/11 19:26 [entrez]
AID - S0163-7258(23)00241-3 [pii]
AID - 10.1016/j.pharmthera.2023.108577 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2024 Jan;253:108577. doi: 10.1016/j.pharmthera.2023.108577. Epub 
      2023 Dec 9.